Home Clinical Trials
Study of Ketamine for Youth Depression (SKY-D)

The primary aim of this research project is to determine if a 4-week course of low-dose subcutaneous ketamine is an effective treatment for young people (males and females aged 16-25 years) with moderate-to-severe depression. Participants will be randomised to receive either low-dose subcutaneous ketamine or a blinded control treatment that is therapeutically inactive (midazolam), given once a week for 4 weeks. Change in depression scores will be assessed at the end of the treatment phase at week 4, with further assessment at weeks 8 and 26 to assess whether treatment effects are sustained. It is hypothesised that ketamine will be an effective treatment for moderate-to-severe depression in young people.

Subjects
Depression / Mental Health
Date made available
Data will be available Immediately following publication, for an indefinite time.
Data set type
IPD
ANZCTR reference number
Publication
Schwartz, O.S., Amminger, P., Baune, B.T. et al. The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder. Trials 24, 686 (2023). https://doi.org/10.1186/s13063-023-07631-3.
Dataset Access Link
Data dictionary
Share